<DOC>
	<DOCNO>NCT02443090</DOCNO>
	<brief_summary>To evaluate safety efficacy fispemifene men secondary hypogonadism sexual side effect .</brief_summary>
	<brief_title>Safety Efficacy Study Oral Fispemifene Treatment Sexual Dysfunction Hypogonadal Men</brief_title>
	<detailed_description>This phase 2 study double-blind , placebo control , parallel arm study 4 week run-in 8-week treatment period . It assess safety tolerability fispemifene , effect treatment sexual side effect see patient population use PRO endpoint .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>A confirmed diagnosis secondary hypogonadism Mild moderate erectile dysfunction Ability read , understand complete diary questionnaires Ability safely make sexual attempt course study Primary hypogonadism Hypogonadism result surgery , trauma , tumor radiation hypothalamus pituitary History current diagnosis breast cancer , prostate cancer and/or PSA level â‰¥3.5 ng/mL Poorly control blood pressure , type 2 diabetes , thyroid disease ; sleep apnea Elevated prolactin level Hemoglobin &gt; 17 g/dL Hematocrit &gt; 50 % Use transdermal oral testosterone within 4 week , intramuscular testosterone therapy within 6 week , testosterone pellet within 6 month prior Screening time throughout study Use another SERM past participation trial Fispemifene Use medication know alter HPG axis Clinically significant finding physical exam , screen lab , finding would prevent safe participation study Participation another clinical study last 30 day</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>secondary hypogonadism</keyword>
	<keyword>sexual dysfunction</keyword>
	<keyword>erectile dysfunction</keyword>
</DOC>